



Published in final edited form as:

Nat Med. 2021 November ; 27(11): 1885–1892. doi:10.1038/s41591-021-01552-x.

## Reporting guidelines for Human Microbiome Research: the STORMS checklist

*A full list of authors and affiliations appears at the end of the article.*

### Abstract

The particular interdisciplinary nature of human microbiome research makes organization and reporting of results spanning epidemiology, biology, bioinformatics, translational medicine, and statistics a challenge. Commonly used reporting guidelines for observational or genetic epidemiology studies lack key features specific to microbiome studies. Therefore a multidisciplinary group of microbiome epidemiology researchers adapted guidelines for observational and genetic studies to culture-independent human microbiome studies, also developing new reporting elements for laboratory, bioinformatic, and statistical analyses tailored to microbiome studies. The resulting tool, named Strengthening The Organization and Reporting of Microbiome Studies (STORMS), is composed of a 17-item checklist organized into six sections corresponding to the typical sections of a scientific publication, presented as an editable table for inclusion in supplementary materials. STORMS provides guidance for concise and complete reporting of microbiome studies that will facilitate manuscript preparation, peer review, reader comprehension of publications, and comparative analysis of published results.

### Introduction

Changes in the human microbiome have been associated with many disease and health states<sup>1</sup>. However, reporting the results of human microbiome research is challenging as it often involves approaches from microbiology, genomics, biomedicine, bioinformatics,

Corresponding Author: Levi Waldron, CUNY Graduate School of Public Health and Health Policy, Institute for Implementation Science in Public Health, 55 W 125<sup>th</sup> St New York, NY 10027, USA levi.waldron@sph.cuny.edu.

\*These authors contributed equally to this work.

#### Author Contributions

The Genomic Standards Consortium and Massive Analysis and Quality Control Society provided feedback and approved the final checklist; C.M., A.R., J.B.D., H.E.J., and L.W. conceived of the checklist; C.M., A.R., J.v.d.W., N.S., C.H., J.B.D., H.E.J., and L.W. developed the checklist; C.M., F.Z., S.E., R.A., J.B.D., H.E.J., L.W. tested the checklist; C.M. and L.W. drafted the manuscript; F.Z.M. created manuscript headings and analytical sample size flowchart figures; C.M. created supplemental tables; A.R., F.Z., S.E., L.G., L.K., K.E., J.v.d.W., A.L., F.Z.M., D.M., M.A., R.A., F.Beghini, K.B., A.B., J.Bisanz, H.C.B., G.B., F.Bushman, D.C., G.C., M.C.C., P.C., J.F.C., R.T.D., S.D., E.E., J.F., R.D.F., A.F., S.F., A.F., C.F., J.G., E.G., B.H.-K., S.Handley, P.H., S.Holmes, J.J., L.K., R.K., D.Knights, O.K., D.Kown, M.L., B.L., D.P.B.M., A.C.M., S.M., N.M., L.N., M.O., N.P., E.P., J.R., M.R.R., J.S.E., M.R., R.B.S., P.D.S., L.S., E.Segal, M.S., T.S., E.Smirnova, H.S., J.L.S., S.S., L.B.T., P.J.T., V.U., R.W., P.W., G.Z., M.Z., N.Z., N.S., J.B.D., H.E.J., and C.H. provided feedback on the checklist and manuscript; all authors reviewed and approved the manuscript.

#### Competing Interests Disclosure

J.S.E. is employed by a research center that belongs to a food company (Grupo Empresarial Nutresa). T.J.S. is a shareholder for Resilient Biotics. HS received unrestricted study grants from Biocodex; board membership, consultancy, or lecture fees from Carenity, Abbvie, Astellas, Danone, Ferring, Mayoly Spindler, M.S.D., Novartis, Roche, Tillots, Enterome, Maat, BiomX, Biose, Novartis, and Takeda; and is a co-founder of Exeliom bioscience. L.B.T. is an employee and shareholder of BiomCare. P.W. is listed as an inventor on patents PCT/EP2012/065178 and PCT/EP2013/052134, and is a member of the scientific steering committee for a clinical trial by 4D Pharma plc. T.Y. is a Founder and Board Member of Metabologenomics Inc. and Metagen Therapeutics Inc. L.Z. is a co-founder of the Notitia Biotechnologies Company. All other authors declare no competing interests

statistics, epidemiology, and other fields, resulting in a lack of consistent recommendations for reporting of methods and results. Inconsistent reporting can have consequences for the field by affecting the reproducibility of study results<sup>2</sup>. While researchers have called for better reporting standards,<sup>3</sup> such as the Genomic Standards Consortium's MIXS checklist<sup>4</sup>, to provide a means for reporting sampling, processing and data generation; no comprehensive standardized guidelines spanning laboratory and epidemiological reporting have been proposed.

Standard reporting guidelines promote research consistency and, as a consequence, encourage reproducibility and improved study design. Editorial adoption of the CONSolidated Standards Of Reporting Trials (CONSORT) guidelines, for example, has been associated with an increase in quality of trial reporting<sup>5,6</sup>. Other epidemiological reporting guidelines have seen broad adoption, such as Strengthening the Reporting of OBservational studies in Epidemiology (STROBE)<sup>7</sup> and STrengthening the REporting of Genetic Association Studies (STREGA)<sup>8</sup>. STROBE-metagenomics<sup>9</sup> proposes an extension to the STROBE checklist for metagenomics studies. Subsequent to the Minimum Information About a Microarray Experiment (MIAME)<sup>9</sup>, Minimum Information about a MARKer gene Sequence (MIMARKS) and Minimum Information about any (x) Sequence (MIXS) checklists provide detailed guidance on reporting of sequencing studies in general. These are focused on the technical aspects of data generation, however, as are projects such as the Microbiome Quality Control Project (MBQC)<sup>10</sup> and International Human Microbiome Standards (IHMS)<sup>11,12</sup>. Together, these serve as useful foundations, but do not span the full range of reporting of human microbiome studies, include items intended for other types of studies, and provide limited guidance on manuscript preparation.

Studies of the human microbiome share many features with other types of molecular epidemiology, but also require unique considerations with their own methodological best practices and reporting standards. In addition to standard elements of epidemiological study design, culture-independent microbiome studies involve collection, handling and preservation of biological specimens, evolving approaches to laboratory processing with elevated potential for batch effects, bioinformatic processing, statistical analysis of sparse, unusually-distributed, high-dimensional data, and reporting of results on potentially thousands of microbial features<sup>13-15</sup>. Because there is no agreed-upon gold-standard method for microbiome research and the field has not reached consensus on many of these aspects, inconsistencies in reporting inhibit reproducibility and hamper efforts to draw conclusions across similar studies.

For these reasons, we convened a multi-disciplinary working group to develop guidelines tailored to microbiome study reporting. Members of this group include epidemiologists, biostatisticians, bioinformaticians, physician-scientists, genomicists, and microbiologists. The checklist is designed to balance completeness with burden of use, and is applicable to a broad range of human microbiome study designs and analysis. The "Strengthening The Organizing and Reporting of Microbiome Studies (STORMS)" checklist (Table S1) draws relevant items from related guidelines and adds new tailored guidelines to serve as a tool to organize study planning and manuscript preparation, to improve the clarity of manuscripts, and to facilitate reviewers and readers in assessing these studies.

## Methodology

### Origin and development

The origins of these guidelines are rooted in a project to create a standardized database of published literature reporting relationships between the microbiome and disease ([bugsigdb.org](https://bugsigdb.org), in preparation). The goal of that project is to create a publicly available, standardized database of microbiome study findings indexed by condition of interest (e.g. disease, health status, diet, environmental factor) microbiome site (e.g. gut, mouth, skin), and microbial taxonomy to aid comparative analysis. As of August 2021, 31 curators (Table S2) have extracted findings from 513 unique published studies (Table S3). Included studies must have examined the relationship between the microbiome and a condition of interest and included findings on a taxonomic level (even if all findings were null).

This review revealed substantial reporting heterogeneity, particularly for epidemiology, such as study design, confounding factors, and sources of bias. It also revealed microbiome-specific issues, including statistical analysis of compositional relative abundance data and handling ‘batch’ effects.<sup>16</sup> This heterogeneity highlighted the need for standardized reporting guidelines, similar to those used in other fields of study. The curators determined that standardized reporting guidelines would streamline the review process, but would more importantly help researchers throughout the field of microbiome research communicate their findings effectively.

The resulting multidisciplinary group of bioinformaticians, epidemiologists, biostatisticians, and microbiologists was thus convened to discuss microbiome reporting standards. The group began by reviewing existing reporting standards including STROBE<sup>17</sup>, STROBE-ME<sup>18</sup>, STREGA<sup>8</sup>, MICRO<sup>19</sup>, MIMARKS<sup>4</sup>, and STROGAR<sup>20</sup>. The group also reviewed existing articles containing recommendations for microbiome reporting<sup>21,22</sup>. The STROBE and STREGA guidelines were used as a starting point for the STORMS checklist, although aspects were incorporated from the other reporting standards.

Following the reporting standards development guidelines recommended by EQUATOR, a comprehensive list of potential guideline items was created. From this list, group members added, modified, and removed items based on their expertise. After the first round of edits, the checklist was then applied to a recent microbiome study<sup>23</sup> by group members. Comments, removals, and additions were harmonized after each round. Based on this process, additional changes, simplifications, and clarifications were made. This process was repeated until there was a group consensus that the checklist was ready for use.

In addition to the core working group, outside subject matter experts identified by working group members were then invited to review the guidelines and provide feedback as members of the STORMS Consortium. Substantive feedback (i.e. not grammar, spelling, or other small changes) from 46 authors was organized by topic and compiled into a feedback document (Supplement 1), and responded to as in a response to reviewers letter. After this round of revisions, consortium members were once again invited to review the checklist prior to submission for publication.

## Elaboration and explanation of checklist items

### Checklist

The latest version of the checklist at time of publication is presented in Table S1 and a summary of items is presented in Figure 1. Of the items in the latest version in the STORMS checklist, nine items or sub-items were unchanged from STROBE, three were modified from STROBE, one was modified from STREGA, and 57 new guidelines were developed. Nine Items with an overlap with MIxS are specified. Rationale for new and modified items are presented below. Documentation of items unmodified from STROBE and STREGA were presented in the publications of those checklists.

**Abstract (1.0-1.3)**—Along with commonly included abstract materials such as a basic description of the participants and results, authors should report the study design<sup>24</sup>--such as cross-sectional, case-control, cohort, or randomized controlled trial--in the abstract of their article (item 1.1), as required by other reporting guidelines. Communicating study design in the abstract allows readers to quickly categorize the type of evidence provided. As part of this basic description, sequencing methods should be mentioned (item 1.2). Body site(s) sampled should also be included (item 1.3).

**Introduction (2.0-2.1)**—The introduction should clearly describe the underlying background, evidence, or theory that motivated the current study (item 2.0). Among other possibilities, this could include pilot study data, previous findings from a similar study or topic, or a biologically plausible mechanism that has been proposed. This clarifies for the reader the motivations for the present study. If the study is exploratory in nature, it should be explained what motivated the current exploration and the goals of the exploratory study. The hypothesis developed based on the background should be included. If the study was exploratory and did not define a hypothesis, pre-specified study objectives should be included (item 2.1).

### Methods (3.0-8.5)

**Participants (3.0-3.9):** The methods section should contain sufficient information for study replicability. Because study design is essential to understanding the study, it should be stated in the methods (item 3.0). When describing the participants in the study, the population of interest should be described and how participants were sampled from the source population (item 3.1). Because participant characteristics such as environment<sup>25</sup>, lifestyle behaviors, diet, biomedical interventions, demographics<sup>26</sup>, and geography<sup>27</sup> (item 3.2) can correspond with substantial differences in the microbiome, it is essential to include this description. Temporal context can be quite important as well so start and end dates for recruitment, follow-up, and data collection should be stated (item 3.3).

Specific criteria used to assess potential participants for eligibility in the study should also be reported, detailing both inclusion and exclusion criteria (item 3.4). Inclusion and exclusion criteria are pre-established characteristics used for selection of participants into the study, and describing these criteria is essential in understanding the study's target population<sup>28</sup>. This is expanded from STROBE, which requires eligibility criteria, but does

not specify that both inclusion and exclusion criteria should be reported in detail. Any information collected about antibiotics or other treatments that could affect the microbiome should be described (item 3.5) as well as if any exclusion criteria included recent antibiotic or other medication use.

The final analytic sample sizes and read numbers should be stated as well as the reason for any exclusion of participants at any step of the recruitment, follow-up, or laboratory processes (item 3.6). STROBE suggests using a flow diagram to show when and why participants were removed from the study. A template for such flow diagrams is presented in Figure 2 and available in an editable spreadsheet (Table S1), and a public domain version for re-use at <https://stormsmicrobiome.org>. If participants were lost to follow-up or did not complete all assessments in a longitudinal study, details on how follow-ups were conducted should be stated and time-point specific sample sizes should also be reported (item 3.7). Additionally, studies that matched cases to controls should describe what variables were used in matching (item 3.4).

**Laboratory methods (4.0-4.17):** Since STROBE does not cover laboratory methods, new items were developed for STORMS. Describe laboratory methods in sufficient detail to allow replication. The handling of lab samples should be described, including procedures for sample collection (items 4.1), shipping (item 4.2), and storage (item 4.3).

Because DNA extraction can be a major source of technical differences across studies,<sup>10</sup> DNA extraction methods should be described (item 4.4). Human DNA removal and microbial DNA enrichment, if performed, should also be included (item 4.5). Likewise, if positive controls (item 4.7), negative controls (item 4.8), or contaminant mitigation methods (item 4.9) were used, they should be identified and described.

Sequencing-related methods should be reported. This includes primer selection and DNA amplification (including the variable region of the 16S rRNA gene if applicable) (item 4.6). Major divisions of sequencing strategy, such as shotgun or amplicon sequencing, should be identified (item 4.11). Finally, the methods used to determine relative abundances should be explained (item 4.12) and the read numbers that serve as denominators recorded.

Batch effects should be discussed as a potential source of confounding, including steps taken to ensure batch effects do not overlap with exposures or outcomes of interest (item 4.13)<sup>29</sup>. If conducting metatranscriptomics, metaproteomics, or metabolomics, provide details of those methods (items 4.14 to 4.16).

**Data sources/measurement (5.0):** For non-microbiome data (e.g. health outcomes, participant socioeconomic, behavioral, dietary, biomedical characteristics, including disease location and activity, and environmental variables), the measurement and definition of each variable should be described (item 5.0). For instance, participant sex and age could be obtained from electronic medical records or from a questionnaire distributed to participants; this data source should be described. Limitations of measurement may also be discussed including potential bias due to misclassification or missing data, as well as any attempts made to address these measurement issues.

**Research design considerations for causal inference (6.0-6.1):** Observational data is often used to test associations that aim towards causal inference in situations where the hypothesized causal relationship is not directly observed. Methods include, for example, the use of multivariable analysis or matching to adjust for confounding variables between a hypothesized exposure (such as abundance of a microbial taxon) and the disease or condition under study<sup>30</sup>. Confounders can be thought of as common causes of the exposure and the outcome under study that can induce a spurious association between the exposure and the outcome<sup>31,32</sup>. For instance, age could be a common confounder due to its significant influence on the microbiome and on risk of most health outcomes<sup>33</sup>. Laboratory batch effects could also confound relationships between the microbiome and a condition of interest if steps are not taken to avoid imbalance of the condition across batches<sup>34</sup>. A common method for attempting to control for confounding is to adjust for or stratify on the confounder<sup>31</sup>. Justification should be provided for variables included or excluded in regression models for causal inference (item 6.0), as adjusting for or stratifying on a non-confounding variable can introduce bias<sup>35</sup>. As part of this theoretical justification, consider including a directed acyclic graph showing the hypothesized causal relationships of interest<sup>36,37</sup>.

In addition to considering the theoretical motivations for the present study, discuss the potential for selection or survival bias which can distort the observed relationship between the microbiome and variable of interest (item 6.1). For example, such bias may occur due to loss-to-follow-up (in longitudinal studies) or due to participants not being included in the study due to the condition itself (e.g. participants who have died of aggressive forms of colorectal cancer have not survived to be in a hypothetical study of colorectal cancer microbiomes)<sup>38</sup>. Other items elsewhere in the checklist may be directly relevant to questions of causal inference including hypotheses (item 2.1), study design (item 3.0), matching (item 3.8), bias (item 13.1) and generalizability (item 13.2). Authors investigating causal questions are encouraged to consider their reporting on these items in the context of causal inference as well.

**Bioinformatics and Statistical Methods (7.0-7.9):** Adequate description of bioinformatic and statistical methods is essential to producing a rigorous and reproducible research report. Data transformations (such as normalization, rarefaction, and percentages) should be described (item 7.0). Quality control methods should be fully disclosed including criteria for filtering or removing reads or samples (item 7.1). All statistical methods used to analyze the data should be stated, (item 7.3) including how results of interest were selected (e.g. using a p-value, q-value, or other threshold) (item 7.8). Taxonomic, functional profiling, or other sequence analysis methods should be described in detail (item 7.2). In the interest of reproducibility, all software, packages, databases, and libraries used for the pre-processing and analysis of the data should be described and cited including version numbers (item 7.9).

**Reproducible Research (8.0-8.5):** Reproducible research practices serve as quality checks in the process of publication and further transparency and knowledge sharing, as detailed in the rubric proposed by Schloss<sup>39</sup>. Journals are increasingly implementing reproducible research standards that include the publishing of data and code, and those guidelines should be followed when possible<sup>40,41</sup>. STORMS itemizes the accessibility of data, methods, and



code (items 8.0 through 8.5). If possible, raw (item 8.1) and processed (item 8.2) data should be deposited into independently-maintained public repositories that provide long-term availability, such those maintained by NCBI or EMBL-EBI. Repositories like Zenodo (<https://zenodo.org/>) or Publisso (<https://www.publisso.de/en/>) can be used to provide a DOI to processed datasets. If data or code are not or cannot be made publicly available, even in a repository that provides restricted-access options, a description of how interested readers can access the data should be provided. As stated in item 8.0, any protected information should be described along with how such data can be accessed.

## Results (9.0-10.4)

**Descriptive Data (9.0):** Descriptive statistics about the study population should be reported (item 9.0). At a minimum, age and sex of all participants should be reported, but other important participant characteristics should be reported when possible including medication use or lifestyle factors such as diet. Consider reporting these data in a descriptive statistics table. Packages such as the `table1` package in R make creating such a table straightforward<sup>42</sup>.

**Outcome Data (10.0-10.4):** The main outcomes of the study should be detailed including descriptive information, findings of interest, and the results of any additional analyses. Descriptive microbiome analysis (for instance, dimension reduction such as Principal Coordinates Analysis, measures of diversity, gross taxonomic composition) should be reported for each group and each time point (item 10.0). This contextualizes the results of differential abundance analysis for readers. When reporting differential abundance test results, the magnitude and direction of differential abundance should be clearly stated (item 10.2) for each identifiable standardized taxonomic unit (item 10.1). Results from other types of analyses such as metabolic function, functional potential, MAG assembly, and RNAseq should be described in the results as well (items 10.3 and 10.4). Additional results (e.g. non-significant results or full differential abundance results) can be included in supplements, but should not be excluded entirely. Although the problem has been known for decades<sup>40</sup>, journals across many fields are recognizing the issue of publication bias and therefore the issue of non-reporting of null results<sup>43</sup>. Including such results in publications will help to reduce the severity of this bias and improve future systematic reviews and meta-analyses.

**Discussion (11.0-14.0)**—Most recommendations for the Discussion section are similar to STROBE including a discussion of the limitations of the present study and associated methods (item 13.0). One additional recommendation is made: discuss the potential for biases and how they would influence the study findings (item 13.1). Many forms of bias such as residual/unmeasured confounding, bias related to compositional analysis<sup>44</sup>, measurement bias, or selection bias<sup>45</sup> could affect the interpretation of the results of the study and it is important to acknowledge potential sources of bias when discussing the results<sup>46</sup>. As described in STROBE, authors should also consider the generalizability of their findings and if these findings could be applicable to the target population or other populations (item 13.2). If different forms of bias were not assessed or assumed to be negligible, this should be stated. Finally, authors should discuss potential future or ongoing research based on findings of the present study (item 14.0).

**Other Information (15.0-17.0)**—In addition to a statement of funding (item 15.0), authors should also include acknowledgements and conflicts of interest statements (items 15.1 and 15.2, respectively). Conflicts of interest statements should be written according to the criteria established by the journal. Finally, the paper should state where supplementary materials and data can be accessed (items 16.0 and 17.0).

## Implementation

The STORMS checklist can streamline peer review by providing both a checklist for assessing for completeness and a roadmap with pointers to the manuscript. Prior to submission, we recommend that authors use the “Comments” field to provide explanations where warranted, and to refer to relevant sections of the manuscript, to make the work of peer reviewers more straightforward and more accurate. We provide two examples of pre-publication use of STORMS: i) a multi-site study of associations between essential hypertension and gut microbial metabolic pathways<sup>47</sup>, and ii) an observational study of the stool microbiota of multiple host species<sup>48</sup>. Additional post-publication examples are also available<sup>49,50</sup>, which highlight that references to line numbers either must be updated during production or will continue to refer to the pre-print version.

## Discussion

The STORMS checklist for reporting on human microbiome studies was developed with the following priorities. The checklist should 1) be easy to understand and use by researchers from various fields, through straightforward use of language and pruning of items rarely relevant to the current literature, 2) be organized in the outline of a manuscript, so it can serve as a tool for authors and for peer reviewers, particularly when included in manuscript submission as a supplemental table with comments, 3) assist in the complete and organized reporting of a study, not in enforcing any particular methods, 4) reuse or modify items from related checklists where relevant, and 5) represent consensus across a broad cross-section of the human microbiome research community. The checklist facilitates manuscript authors in providing a complete, concise, and organized description of their study and its findings. Included as a supplemental table to a manuscript, it also supports efficient peer review and post-publication interpretation.

While other efforts for extending STROBE for microbiome and metagenomic have been proposed<sup>9</sup> and laboratory-focused reporting checklists have been released<sup>4,51</sup>, to our knowledge STORMS is the first comprehensive reporting checklist for human microbiome research. We aim for the STORMS guidelines to improve the quality and transparency of microbiome epidemiology studies by introducing a shared grammar of study reporting in a structured checklist format. Reporting checklists introduced in other disciplines have been shown to improve the quality of journal articles<sup>5,6</sup>.

A major strength of STORMS is the rigor and transparency of its development by a diverse, multidisciplinary consortium of subject matter experts. All feedback received from consortium members, and responses, have been included as Supplement 1. The development of STORMS is an ongoing process, and new versions of the checklist will be released to reflect evolving standards and technological processes. A version control



system with changelog has been implemented, and annual reviews of the checklist are planned. Additionally, the working group plans to evaluate STORMS impact on microbiome reporting by examining how many articles are fulfilling checklist items before and after its release. We invite interested readers to join the STORMS Consortium by contacting the corresponding author or by visiting the consortium website for more information (<https://www.stormsmicrobiome.org/>). We also encourage journals to include the STORMS checklist in their instructions to authors and advise peer reviewers to consult the checklist when reviewing submissions.

There are some limitations to the STORMS checklist. The checklist was not created to assess study or methodological rigor. It is meant to aid authors' organization and ease the process of reader assessment of how studies are conducted and analyzed. Conclusions about the quality of studies should not be made based on their adherence to STORMS guidelines, although we expect the reporting guidelines to help readers review studies critically. It does not encourage, discourage, or assume the use of null hypothesis significance testing<sup>52</sup> or methods of compositional data analysis<sup>53</sup>, topics of some controversy in the field. In general the checklist avoids reference to or guidance on specific statistical methodological decisions.

Through the efforts of the STORMS Consortium working in an iterative, transparent, and collaborative process, the STORMS checklist provides a roadmap for researchers in reporting the results of a human microbiome study. The STORMS Consortium believes that the checklist is sufficiently flexible and user-friendly to support widespread adoption and contribution to microbiome study standards. Its adoption will ideally encourage thoughtful study design, reproducibility, collaboration, and open knowledge sharing between research groups as they explore the human microbiome.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Authors

Chloe Mirzayi<sup>1</sup>, Audrey Renson<sup>2</sup>, Genomic Standards Consortium, Massive Analysis and Quality Control Society, Fatima Zohra<sup>1</sup>, Shaimaa Elsafoury<sup>1</sup>, Ludwig Geistlinger<sup>1</sup>, Lora Kasselmann<sup>1</sup>, Kelly Eckenrode<sup>1</sup>, Janneke van de Wijkert<sup>3</sup>, Amy Loughman<sup>4</sup>, Francine Z. Marques<sup>5</sup>, David MacIntyre<sup>6</sup>, Manimozhiyan Arumugam<sup>7</sup>, Rimsha Azhar<sup>1</sup>, Francesco Beghini<sup>8</sup>, Kirk Bergstrom<sup>9</sup>, Ami Bhatt<sup>10</sup>, Jordan Bisanz<sup>11</sup>, Jonathan Braun<sup>12</sup>, Hector Corrada Bravo<sup>13</sup>, Gregory Buck<sup>14</sup>, Frederic Bushman<sup>15</sup>, David Casero<sup>16</sup>, Gerard Clarke<sup>17</sup>, Maria Carmen Collado<sup>18</sup>, Paul Cotter<sup>19</sup>, John F. Cryan<sup>20</sup>, Ryan T. Demmer<sup>21</sup>, Suzanne Devkota<sup>16</sup>, Eran Elinav<sup>22</sup>, Jennifer Fettweis<sup>14</sup>, Robert D. Finn<sup>23</sup>, Anthony Fodor<sup>24</sup>, Sofia Forslund<sup>25</sup>, Andre Franke<sup>26</sup>, Cesare Furlanello<sup>27</sup>, Jack Gilbert<sup>28</sup>, Elizabeth Grice<sup>29</sup>, Benjamin Haibe-Kains<sup>30</sup>, Scott Handley<sup>31</sup>, Pamela Herd<sup>32</sup>, Susan Holmes<sup>33</sup>, Jonathan Jacobs<sup>34</sup>, Lisa Karstens<sup>35</sup>, Rob Knight<sup>36</sup>, Dan Knights<sup>37</sup>, Omry Koren<sup>38</sup>, Douglas Kwon<sup>39</sup>, Morgan Langille<sup>40</sup>, Brianna Lindsay<sup>41</sup>, Dermot McGovern<sup>16</sup>, Alice C. McHardy<sup>42</sup>, Shannon McWeeney<sup>43</sup>, Noel Mueller<sup>44</sup>, Luigi Nezi<sup>45</sup>, Matthew Olm<sup>46</sup>, Noah Palm<sup>47</sup>,

Edoardo Pasolli<sup>48</sup>, Jeroen Raes<sup>49</sup>, Matthew R. Redinbo<sup>50</sup>, Juan S. Escobar<sup>51</sup>, Malte Rühlemann<sup>52</sup>, R. Balfour Sartor<sup>53</sup>, Patrick D Schloss<sup>54</sup>, Lynn Schriml<sup>55</sup>, Eran Segal<sup>56</sup>, Michelle Shardell<sup>55</sup>, Thomas Sharpton<sup>57</sup>, Ekaterina Smirnova<sup>58</sup>, Harry Sokol<sup>59</sup>, Justin L. Sonnenburg<sup>60</sup>, Sujatha Srinivasan<sup>61</sup>, Louise B. Thingholm<sup>62</sup>, Peter J. Turnbaugh<sup>11</sup>, Vaibhav Upadhyay<sup>63</sup>, Ramona Walls<sup>64</sup>, Paul Wilmes<sup>65</sup>, Takuji Yamada<sup>66</sup>, Georg Zeller<sup>67</sup>, Mingyu Zhang<sup>44</sup>, Ni Zhao<sup>68</sup>, Liping Zhao<sup>69</sup>, Wenjun Bao<sup>70</sup>, Aedin Culhane<sup>71</sup>, Viswanath Devanarayan<sup>72</sup>, Joaquin Dopazo<sup>73</sup>, Xiaohui Fan<sup>74</sup>, Matthias Fischer<sup>75</sup>, Wendell Jones<sup>76</sup>, Rebecca Kusko<sup>77</sup>, Christopher Mason<sup>78</sup>, Timothy Mercer<sup>79</sup>, Susanna-Assunta Sansone<sup>80</sup>, Andreas Scherer<sup>81</sup>, Leming Shi<sup>82</sup>, Shraddha Thakkar<sup>83</sup>, Weida Tong<sup>84</sup>, Russ Wolfinger<sup>85</sup>, Christopher Hunter<sup>86</sup>, Nicola Segata<sup>87</sup>, Curtis Huttenhower<sup>88,\*</sup>, Jennifer B. Dowd<sup>89,\*</sup>, Heidi E. Jones<sup>1,\*</sup>, Levi Waldron<sup>1,\*</sup>

## Affiliations

<sup>1</sup>CUNY Graduate School of Public Health and Health Policy, Institute for Implementation Science in Public Health, New York, NY USA

<sup>2</sup>University of North Carolina, Chapel Hill USA

<sup>3</sup>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands

<sup>4</sup>Food & Mood Centre, The Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University, Victoria, Australia.

<sup>5</sup>Hypertension Research Laboratory, School of Biological Sciences, Faculty of Science, Monash University, Melbourne, Australia

<sup>6</sup>Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK

<sup>7</sup>Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark

<sup>8</sup>University of Trento, Center for Integrative Biology, Trento, Italy

<sup>9</sup>Department of Biology, University of British Columbia - Okanagan Campus, Kelowna, BC, Canada

<sup>10</sup>Departments of Medicine (Hematology & BMT) and Genetics | Stanford University, Stanford, CA

<sup>11</sup>Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA

<sup>12</sup>Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

<sup>13</sup>Genentech, Inc., South San Francisco, CA, USA

- <sup>14</sup>Department of Microbiology and Immunology, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA
- <sup>15</sup>University of Pennsylvania, Philadelphia, PA, USA
- <sup>16</sup>F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- <sup>17</sup>Department of Psychiatry and Neurobehavioural Science, and APC Microbiome Ireland, University College Cork, Cork, Ireland
- <sup>18</sup>Institute of Agrochemistry and Food Technology-National Research Council (IATA-CSIC), Valencia, Spain
- <sup>19</sup>Teagasc Food Research Centre, Moorepark, Cork, APC Microbiome Ireland and VistaMilk, Ireland
- <sup>20</sup>Department of Anatomy and Neuroscience and APC Microbiome Ireland, University College Cork, Cork, Ireland
- <sup>21</sup>School of Public Health, University of Minnesota, Minneapolis, MN, USA
- <sup>22</sup>Immunology Department, Weizmann Institute of Science, Rehovot, Israel & Microbiome and Cancer Division, DKFZ, Heidelberg, Germany
- <sup>23</sup>European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK
- <sup>24</sup>Department of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, North Carolina, USA.
- <sup>25</sup>Experimental and Clinical Research Center, Max-Delbrück-Center for Molecular Medicine and Charité University Hospital, Berlin, Germany
- <sup>26</sup>Institute of Clinical Molecular Biology, Kiel University, Kiel, Germany.
- <sup>27</sup>HK3 Lab, Rovereto (TN), Italy
- <sup>28</sup>Department of Pediatrics and Scripps Institution of Oceanography, University of California, San Diego, La Jolla, CA, USA
- <sup>29</sup>Department of Dermatology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA
- <sup>30</sup>Princess Margaret Cancer Centre, Toronto, Canada
- <sup>31</sup>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
- <sup>32</sup>McCourt School of Public Policy, Georgetown University, Washington, DC, USA
- <sup>33</sup>Department of Statistics, Stanford University, Stanford, California, USA
- <sup>34</sup>Division of Digestive Diseases, David Geffen School of Medicine at UCLA
- <sup>35</sup>Oregon Health & Science University, Portland, OR, USA

<sup>36</sup>Center for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA

<sup>37</sup>Department of Computer Science and Engineering, University of Minnesota, Minneapolis, MN, USA; Biotechnology Institute, University of Minnesota, Saint Paul, Minnesota, USA

<sup>38</sup>Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel

<sup>39</sup>Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA

<sup>40</sup>Department of Pharmacology, Dalhousie University, Halifax, B3H 4R2, Nova Scotia, Canada

<sup>41</sup>University of Maryland School of Medicine, Institute of Human Virology, Baltimore, MD, USA

<sup>42</sup>Department of Computational Biology of Infection Research, Helmholtz Centre for Infection Research, 38124 Brunswick, Germany

<sup>43</sup>OHSU Knight Cancer Institute, Portland, OR, USA

<sup>44</sup>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

<sup>45</sup>Department of Experimental Oncology, IRCCS - Istituto Europeo di Oncologia (IEO), 20139 Milan, Italy

<sup>46</sup>Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA

<sup>47</sup>Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA

<sup>48</sup>Department of Agricultural Sciences, University of Naples Federico II, 80055 Portici, Italy

<sup>49</sup>Department of Microbiology and Immunology, Rega institute, KU Leuven VIB Center for Microbiology KU Leuven - Campus Gasthuisberg Herestraat 49 - box 1028 3000 Leuven

<sup>50</sup>Department of Chemistry, University of North Carolina Chapel Hill, NC, USA

<sup>51</sup>Vidarium--Nutrition, Health and Wellness Research Center, Grupo Empresarial Nutresa, Medellin, Colombia

<sup>52</sup>Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, 24105 Kiel, Germany.

<sup>53</sup>Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA

<sup>54</sup>University of Michigan, Department of Microbiology & Immunology, Ann Arbor, MI, USA

<sup>55</sup>University of Maryland School of Medicine, Institute for Genome Sciences, Baltimore, MD, USA

<sup>56</sup>Department of Computer Science, Weizmann Institute of Science, Rehovot, Israel

<sup>57</sup>Department of Microbiology Department of Statistics Oregon State University Corvallis, OR, USA

<sup>58</sup>Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA

<sup>59</sup>Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, 75012 Paris, France

<sup>60</sup>Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA

<sup>61</sup>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

<sup>62</sup>Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, 24105 Kiel, Germany

<sup>63</sup>University of California, San Francisco

<sup>64</sup>Bio5 Institute, University of Arizona

<sup>65</sup>Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg Department of Life Sciences and Medicine, Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg

<sup>66</sup>Department of Life Science and Technology, Tokyo Institute of Technology, Tokyo, Japan

<sup>67</sup>European Molecular Biology Laboratory, Structural and Computational Biology Unit, Heidelberg, 69117, Germany

<sup>68</sup>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

<sup>69</sup>Department of Biochemistry and Microbiology School of Environmental and Biological Sciences Rutgers University Lipman Hall - Room 326, 76 Lipman Drive New Brunswick, NJ, USA

<sup>70</sup>JMP Life Sciences, SAS Institute, CARY, NC, USA

<sup>71</sup>Dept of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA

<sup>72</sup>Eisai, Inc.

<sup>73</sup>Clinical Bioinformatics Area, Hospital Virgen del Rocio, Sevilla, Spain

<sup>74</sup>College of Pharmaceutical Sciences, Zhejiang University, China

<sup>75</sup>Experimental Pediatric Oncology, University Children's Hospital, and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne, Germany

<sup>76</sup>Q2 Solutions-EA Genomics, USA

<sup>77</sup>Immuneering Corporation, USA

<sup>78</sup>Weill Cornell Medicine, New York, USA

<sup>79</sup>Garvan Institute of Medical Research, University of New South Wales, Australia

<sup>80</sup>Oxford e-Research Centre, Department of Engineering Science, University of Oxford, UK

<sup>81</sup>Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland

<sup>82</sup>State Key Laboratory of Genetic Engineering, Human Phenome Institute, School of Life Sciences and Shanghai Cancer Center, Fudan University, Shanghai, China

<sup>83</sup>Office of Computational Science, OTS, CDER, USA

<sup>84</sup>Division of Bioinformatics and Biostatistics, NCTR/FDA, USA

<sup>85</sup>Scientific Discovery and Genomics, SAS Institute, Cary, NC, USA

<sup>86</sup>GigaScience Database, BGI-Hong Kong

<sup>87</sup>University of Trento, Center for Integrative Biology, Trento, IT

<sup>88</sup>Harvard TH Chan School of Public Health, Boston, MA, USA

<sup>89</sup>University of Oxford, Department of Sociology, Leverhulme Centre for Demographic Science, Oxford UK

## Acknowledgements

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number 5R01CA230551. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additionally, JBD was supported by the Leverhulme Trust.

## Data Availability Statement

The STORMS checklist as a versioned spreadsheet, and the analytical sample size flow diagram as editable PPTX and PDF files, are available for adaptation and inclusion in manuscripts at <https://www.stormsmicrobiome.org/>.

## Consortia Author List

### Genomic Standards Consortium

Robert D. Finn<sup>23</sup>, Lynn Schriml<sup>55</sup>, Ramona Walls<sup>64</sup>, Christopher Hunter<sup>86</sup>, Susanna-Assunta Sansone<sup>80</sup>



<sup>23</sup>European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK, UK, <sup>55</sup>University of Maryland School of Medicine, Institute for Genome Sciences, Baltimore, MD, USA, USA, <sup>64</sup>Bio5 Institute, University of Arizona, USA, <sup>86</sup>GigaScience Database, BGI-Hong Kong, Hong Kong, <sup>80</sup>Oxford e-Research Centre, Department of Engineering Science, University of Oxford, UK, UK

## Massive Analysis and Quality Control Society

Cesare Furlanello<sup>27</sup>, Benjamin Haibe-Kains<sup>30</sup>, Wenjun Bao<sup>70</sup>, Aedin Culhane<sup>71</sup>, Viswanath Devanarayan<sup>72</sup>, Joaquin Dopazo<sup>73</sup>, Xiaohui Fan<sup>74</sup>, Matthias Fischer<sup>75</sup>, Wendell Jones<sup>76</sup>, Rebecca Kusko<sup>77</sup>, Christopher Mason<sup>78</sup>, Timothy Mercer<sup>79</sup>, Andreas Scherer<sup>81</sup>, Leming Shi<sup>82</sup>, Shraddha Thakkar<sup>83</sup>, Weida Tong<sup>84</sup>, Russ Wolfinger<sup>85</sup>, Susanna-Assunta Sansone<sup>80</sup>


<sup>27</sup>HK3 Lab, Rovereto (TN), Italy, Italy, <sup>30</sup>Princess Margaret Cancer Centre, Toronto, Canada, Canada, <sup>70</sup>JMP Life Sciences, SAS Institute, CARY, NC, USA, USA, <sup>71</sup>Dept of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA, USA, <sup>72</sup>Eisai, Inc., USA, <sup>73</sup>Clinical Bioinformatics Area, Hospital Virgen del Rocío, Sevilla, Spain, Spain, <sup>74</sup>College of Pharmaceutical Sciences, Zhejiang University, China, China, <sup>75</sup>Experimental Pediatric Oncology, University Children's Hospital, and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne, Germany, Germany, <sup>76</sup>Q2 Solutions-EA Genomics, USA, USA, <sup>77</sup>Immuneering Corporation, USA, USA, <sup>78</sup>Weill Cornell Medicine, New York, USA, USA, <sup>79</sup>Garvan Institute of Medical Research, University of New South Wales, Australia, Australia, <sup>81</sup>Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland, Finland, <sup>82</sup>State Key Laboratory of Genetic Engineering, Human Phenome Institute, School of Life Sciences and Shanghai Cancer Center, Fudan University, Shanghai, China, China, <sup>83</sup>Office of Computational Science, OTS, CDER, USA, USA, <sup>84</sup>Division of Bioinformatics and Biostatistics, NCTR/FDA, USA, USA, <sup>85</sup>Scientific Discovery and Genomics, SAS Institute, Cary, NC, USA, USA, <sup>80</sup>Oxford e-Research Centre, Department of Engineering Science, University of Oxford, UK, UK

## References


1. Wirbel J et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. *Nat. Med* 25, 679–689 (2019). [PubMed: 30936547]
2. Simoneau J, Dumontier S, Gosselin R & Scott MS Current RNA-seq methodology reporting limits reproducibility. *Brief. Bioinform* doi:10.1093/bib/bbz124.
3. Ten Hoopen P et al. The metagenomic data life-cycle: standards and best practices. *GigaScience* 6, 1–11 (2017).
4. Yilmaz P et al. Minimum information about a marker gene sequence (MIMARKS) and minimum information about any (x) sequence (MIXS) specifications. *Nat. Biotechnol* 29, 415–420 (2011). [PubMed: 21552244]
5. Moher D, Jones A, Lepage L & Group, for the C. Use of the CONSORT Statement and Quality of Reports of Randomized Trials: A Comparative Before-and-After Evaluation. *JAMA* 285, 1992–1995 (2001). [PubMed: 11308436]
6. Plint AC et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. *185*, 5 (2006).
7. Vandembroucke JP et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. *PLOS Med.* 4, e297 (2007). [PubMed: 17941715]

8. STrengthening the REporting of Genetic Association Studies (STREGA)—an extension of the STROBE statement - Little - 2009 - Genetic Epidemiology - Wiley Online Library. <https://onlinelibrary.wiley.com/doi/abs/10.1002/gepi.20410>.
9. Bharucha T et al. STROBE-metagenomics: a STROBE extension statement to guide the reporting of metagenomics studies. *Lancet Infect. Dis* 20, e251–e260 (2020). [PubMed: 32768390]
10. Sinha R et al. Assessment of variation in microbial community amplicon sequencing by the Microbiome Quality Control (MBQC) project consortium. *Nat. Biotechnol* 35, 1077–1086 (2017). [PubMed: 28967885]
11. Costea PI et al. Towards standards for human fecal sample processing in metagenomic studies. *Nat. Biotechnol* 35, 1069–1076 (2017). [PubMed: 28967887]
12. Santiago A et al. Processing faecal samples: a step forward for standards in microbial community analysis. *BMC Microbiol.* 14, 112 (2014). [PubMed: 24884524]
13. Turner P et al. Microbiology Investigation Criteria for Reporting Objectively (MICRO): a framework for the reporting and interpretation of clinical microbiology data. *BMC Med.* 17, 70 (2019). [PubMed: 30922309]
14. STROGAR – STrengthening the Reporting Of Genetic Association studies in Radiogenomics - ScienceDirect. <https://www.sciencedirect.com/science/article/pii/S0167814013003630>.
15. Sinha R, Abnet CC, White O, Knight R & Huttenhower C The microbiome quality control project: baseline study design and future directions. *Genome Biol.* 16, 276 (2015). [PubMed: 26653756]
16. Badal VD et al. Challenges in the construction of knowledge bases for human microbiome-disease associations. *Microbiome* 7, 129 (2019). [PubMed: 31488215]
17. von Elm E et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J. Clin. Epidemiol* 61, 344–349 (2008). [PubMed: 18313558]
18. Gallo V et al. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): an extension of the STROBE statement. *Eur. J. Clin. Invest* 42, 1–16 (2012).
19. Microbiology Investigation Criteria for Reporting Objectively (MICRO): a framework for the reporting and interpretation of clinical microbiology data | BMC Medicine | Full Text. <https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-019-1301-1>.
20. Kerns SL et al. STROGAR – STrengthening the Reporting Of Genetic Association studies in Radiogenomics. *Radiother. Oncol* 110, 182–188 (2014). [PubMed: 23993398]
21. Sinha R et al. Next steps in studying the human microbiome and health in prospective studies, Bethesda, MD, May 16–17, 2017. *Microbiome* 6, (2018).
22. Hornung BVH, Zwitter RD & Kuijper EJ Issues and current standards of controls in microbiome research. *FEMS Microbiol. Ecol* 95, (2019).
23. Min Y et al. Sex-specific association between gut microbiome and fat distribution. *Nat. Commun* 10, (2019).
24. Pearce N Classification of epidemiological study designs. *Int. J. Epidemiol* 41, 393–397 (2012). [PubMed: 22493323]
25. Jin Y, Wu S, Zeng Z & Fu Z Effects of environmental pollutants on gut microbiota. *Environ. Pollut* 222, 1–9 (2017). [PubMed: 28086130]
26. Chen L, Zhang Y-H, Huang T & Cai Y-D Gene expression profiling gut microbiota in different races of humans. *Sci. Rep* 6, 23075 (2016). [PubMed: 26975620]
27. Yatsunenko T et al. Human gut microbiome viewed across age and geography. *Nature* 486, 222–227 (2012). [PubMed: 22699611]
28. Patino CM, Ferreira JC, Patino CM & Ferreira JC Inclusion and exclusion criteria in research studies: definitions and why they matter. *J. Bras. Pneumol* 44, 84–84 (2018). [PubMed: 29791550]
29. Yan L et al. OSAT: a tool for sample-to-batch allocations in genomics experiments. *BMC Genomics* 13, 689 (2012). [PubMed: 23228338]
30. VanderWeele TJ Principles of confounder selection. *Eur. J. Epidemiol* 34, 211–219 (2019). [PubMed: 30840181]

31. Hernán MA, Hernández-Díaz S, Werler MM & Mitchell AA Causal Knowledge as a Prerequisite for Confounding Evaluation: An Application to Birth Defects Epidemiology. *Am. J. Epidemiol* 155, 176–184 (2002). [PubMed: 11790682]
32. Lv B-M, Quan Y & Zhang H-Y Causal Inference in Microbiome Medicine: Principles and Applications. *Trends Microbiol.* (2021) doi:10.1016/j.tim.2021.03.015.
33. Ghosh TS, Das M, Jeffery IB & O'Toole PW Adjusting for age improves identification of gut microbiome alterations in multiple diseases. *eLife* 9, e50240 (2020). [PubMed: 32159510]
34. Soneson C, Gerster S & Delorenzi M Batch Effect Confounding Leads to Strong Bias in Performance Estimates Obtained by Cross-Validation. *PLOS ONE* 9, e100335 (2014). [PubMed: 24967636]
35. Cole SR et al. Illustrating bias due to conditioning on a collider. *Int. J. Epidemiol* 39, 417–420 (2010). [PubMed: 19926667]
36. Textor J, van der Zander B, Gilthorpe MS, Li kiewicz M & Ellison GTH Robust causal inference using directed acyclic graphs: the R package 'dagitty'. *Int. J. Epidemiol* dyw341 (2017) doi:10.1093/ije/dyw341.
37. Loughman A et al. Gut microbiota composition during infancy and subsequent behavioural outcomes. *EBioMedicine* 52, 102640 (2020). [PubMed: 32062351]
38. Schooling CM Selection bias in population-representative studies? A commentary on Deaton and Cartwright. *Soc. Sci. Med.* 1982 210, 70 (2018).
39. Schloss PD Identifying and Overcoming Threats to Reproducibility, Replicability, Robustness, and Generalizability in Microbiome Research. *mBio* 9, (2018).
40. Rosenthal R The file drawer problem and tolerance for null results.
41. Munafò M & Neill J Null is beautiful: On the importance of publishing null results. *J. Psychopharmacol. (Oxf.)* 30, 585–585 (2016).
42. Rich B benjaminrich/table1.
43. Null is beautiful: On the importance of publishing null results - Munafò Marcus, Neill Jo, 2016. <https://journals.sagepub.com/doi/full/10.1177/0269881116638813>.
44. McLaren MR, Willis AD & Callahan BJ Consistent and correctable bias in metagenomic sequencing experiments. *eLife* 8, (2019).
45. Hernán M & Robins JM. *Causal Inference: What If.* (Chapman & Hall/CRC, 2020).
46. Writing a discussion section: how to integrate substantive and statistical expertise | BMC Medical Research Methodology | Full Text. <https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-018-0490-1>.
47. Nakai M et al. Essential Hypertension Is Associated With Changes in Gut Microbial Metabolic Pathways: A Multisite Analysis of Ambulatory Blood Pressure. *Hypertension* 78, 804–815 (2021). [PubMed: 34333988]
48. Thingholm Louise B. et al. Ecology impacts the decrease of Spirochaetes and Prevotella in the fecal gut microbiota of urban humans. *Res. Sq* (2021) doi:10.21203/rs.3.rs-147555/v2.
49. Wang Q et al. Linking gut microbiome to bone mineral density: a shotgun metagenomic dataset from 361 elderly women. *Gigabyte* 2021, 1–7 (2021).
50. Chen C et al. The female urinary microbiota in relation to the reproductive tract microbiota. *Gigabyte* 2020, 1–9 (2020).
51. Raes J, Foerstner KU & Bork P Get the most out of your metagenome: computational analysis of environmental sequence data. *Curr. Opin. Microbiol* 10, 490–498 (2007). [PubMed: 17936679]
52. Szucs D & Ioannidis JPA When Null Hypothesis Significance Testing Is Unsuitable for Research: A Reassessment. *Front. Hum. Neurosci* 11, (2017).
53. Gloor GB, Macklaim JM, Pawlowsky-Glahn V & Egozcue JJ Microbiome Datasets Are Compositional: And This Is Not Optional. *Front. Microbiol* 8, (2017)



**Figure 1.**  
STORMS checklist items by major manuscript heading. For detailed descriptions of each item and additional guidance, see the STORMS checklist (Table S1).



**Figure 2. Examples of flowcharts for item 3.6.**

Though not required by STORMS, flowcharts can help visualize how the final analytic sample was calculated.